PureTech Health PLC
LSE:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
LSE:PRTC
Watchlist
Price: 154.6 GBX -3.25% Market Closed
Market Cap: 370.1m GBX
Have any thoughts about
PureTech Health PLC?
Write Note

PureTech Health PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PureTech Health PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
PureTech Health PLC
LSE:PRTC
Total Current Liabilities
$51.4m
CAGR 3-Years
-34%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

PureTech Health PLC
Glance View

Market Cap
370.1m GBX
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
37.96 GBX
Overvaluation 75%
Intrinsic Value
Price

See Also

What is PureTech Health PLC's Total Current Liabilities?
Total Current Liabilities
51.4m USD

Based on the financial report for Dec 31, 2023, PureTech Health PLC's Total Current Liabilities amounts to 51.4m USD.

What is PureTech Health PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-28%

Over the last year, the Total Current Liabilities growth was -47%. The average annual Total Current Liabilities growth rates for PureTech Health PLC have been -34% over the past three years , -28% over the past five years .

Back to Top